MSD and Eyebiotech have announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio. “We continue to execute on our science-led business development strategy to expand...

Secarna Pharmaceuticals and Orbit Discovery have announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics. The collaboration will leverage Orbit’s expertise and bead-based peptide display engine...

AGC Biologics and BioConnection, a specialised CMO focusing on aseptic filling of vials and syringes for clinical and commercial production, have announced a new strategic partnership. They are partnering to provide end-to-end biopharmaceutical development and manufacturing...

The European Commission has approved, under EU State aid rules, the first Important Project of Common European Interest to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production...

LabGenius has closed a £35 million Series B financing round. The investment brings LabGenius’ total funding to date to £58 million. The round was led by new investor M Ventures (the strategic, corporate venture capital...

Germfree and Orgenesis Inc. have announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs and its suite of product development and GMP cell processing services. The collaboration’s goal is to transform the production...

Bio-Sourcing, with partners Ciloa and Intract Pharma, have announced the launch of a €3.4M ($3.7M) EU-funded program, including €1.9M in subsidies from EUREKA Eurostars. The three-year AB-BIOBETTER project aims to develop an oral antibody...

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly...

Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models...

Aktis Oncology have announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform. The collaboration draws on Aktis’ proprietary radiopharmaceutical platform together with Lilly’s expertise...

Biogen and Human Immunology Biosciences (HI-Bio) have announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone...

Orna Therapeutics have announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18...

Nona Biosciences have announced that it has entered into a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology. “We are delighted to announce this agreement with...

SGD Pharma has invested more than €20 million to upgrade its Zhanjiang plant in China. The refurbishment involves a complete rebuild of its furnace and comprehensive improvement of the plant’s facilities. Using the most advanced...

Merck has signed a definitive agreement to acquire life science company Mirus Bio for $600 million. Mirus Bio is a specialist in the development and commercialisation of transfection reagents. Transfection reagents, such as Mirus Bio’s TransIT-VirusGEN, are used...

Serum Institute of India (SII) has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology. The partnership between SII and IntegriMedical aligns with SII’s vision...